Anbio Biotechnology

Anbio Biotechnology

Health Care Equipment & Supplies
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.

$244.9M

Market Cap • 9/22/2026

2021

(5 years)

Founded

2025

(1 year ago)

IPO

NASDAQ

Listing Exchange

Flag of Germany

Germany

Country

Valuation

P/B

8,1

P/S

28,3

P/EBITDA

42,5

P/OCF

P/FCF

P/E

38

BVPS

0,7

EPS

0,1

Market Cap

Market Cap

244,9M

EV

233M

EV/Revenue

26,9

EV/EBITDA

40,4

EV/EBIT

40,4

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-3%

Total Yield

-3%

Payout

0%

Retained Earnings

23,6M

Profitability

Gross Margin

87,2%

EBITDA Margin

66,7%

EBIT Margin

66,7%

Net Margin

74,1%

D&A/EBITDA

0%

R&D/Revenue

2,3%

Capex/Revenue

0%

Capex/D&A

0%

Capex/OCF

0%

SBC/OCF

% PPE

0%

% Goodwill

0%

ROE

27%

ROIC

48,7%

Leverage

N.D./EBITDA

Debt/Equity

0%

Current Ratio

344,3

Quick Ratio

177,1

Interest Coverage

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium